Shares in Karo Bio AB gained almost 30 percent this week on news that the company's lead drug candidate, the thyroid hormone receptor agonist eprotirome (KB2115) attained the primary endpoints in a Phase IIb trial in patients with elevated blood lipids who already were receiving statins. (BioWorld International)

LONDON - TauRx Therapeutics Ltd. presented positive data on the first tau inhibitor to complete Phase II in the treatment of Alzheimer's disease, showing the drug, rember, slowed the progress of the mild to moderate form of the disorder by 81 percent over 12 months. (BioWorld International)